Cargando…

An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country

Introduction Development of laryngeal cancer is multifactorial, and management is surrounded with controversies. Recent reports suggest a decline in the survival of these patients. We conducted a study to analyze the clinicopathological parameters and compute the outcomes in terms of survival in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Adeel, Mohammad, Faisal, Muhammad, Rashid, Asma, Usman, Sadaf, Khaleeq, Usman, Abbas, Taskheer, Rehman, Abdul, Malik, Kashif, Hussain, Raza, Jamshed, Arif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070066/
https://www.ncbi.nlm.nih.gov/pubmed/30083491
http://dx.doi.org/10.7759/cureus.2730
_version_ 1783343615481741312
author Adeel, Mohammad
Faisal, Muhammad
Rashid, Asma
Usman, Sadaf
Khaleeq, Usman
Abbas, Taskheer
Rehman, Abdul
Malik, Kashif
Hussain, Raza
Jamshed, Arif
author_facet Adeel, Mohammad
Faisal, Muhammad
Rashid, Asma
Usman, Sadaf
Khaleeq, Usman
Abbas, Taskheer
Rehman, Abdul
Malik, Kashif
Hussain, Raza
Jamshed, Arif
author_sort Adeel, Mohammad
collection PubMed
description Introduction Development of laryngeal cancer is multifactorial, and management is surrounded with controversies. Recent reports suggest a decline in the survival of these patients. We conducted a study to analyze the clinicopathological parameters and compute the outcomes in terms of survival in patients with laryngeal cancer treated at our institution. Methods Electronic charts of 515 patients with Laryngeal cancer treated at our Hospital and Research Center from 2004 to 2014 were retrospectively reviewed. Results Median age was 62 years. Male: female ratio 91%: 9%. Sixty-two percent were smokers. Histologically, all were squamous cell carcinoma. Most common subsite was glottis (88%). Treatment was non-surgical in 92% and surgical in 8%. The five-year overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS) and locoregional control (LRC) were 67%, 74%, 59% and 70%, respectively. OS, DSS, DFS and LRC for early stage (I-II) and advance stage (III-IV) were 81 and 54%, 86 and 63%, 75 and 45%, and 83 and 57%, respectively. Twenty-two percent recurred locally. Of these failures, 19% were inoperable, 36% were surgically salvaged and 34% refused laryngectomy. Conclusions Our survival rates are comparable with published data. The high refusal rate for salvage total laryngectomy is concerning and needs further study to evaluate the reasons.
format Online
Article
Text
id pubmed-6070066
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-60700662018-08-06 An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country Adeel, Mohammad Faisal, Muhammad Rashid, Asma Usman, Sadaf Khaleeq, Usman Abbas, Taskheer Rehman, Abdul Malik, Kashif Hussain, Raza Jamshed, Arif Cureus Otolaryngology Introduction Development of laryngeal cancer is multifactorial, and management is surrounded with controversies. Recent reports suggest a decline in the survival of these patients. We conducted a study to analyze the clinicopathological parameters and compute the outcomes in terms of survival in patients with laryngeal cancer treated at our institution. Methods Electronic charts of 515 patients with Laryngeal cancer treated at our Hospital and Research Center from 2004 to 2014 were retrospectively reviewed. Results Median age was 62 years. Male: female ratio 91%: 9%. Sixty-two percent were smokers. Histologically, all were squamous cell carcinoma. Most common subsite was glottis (88%). Treatment was non-surgical in 92% and surgical in 8%. The five-year overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS) and locoregional control (LRC) were 67%, 74%, 59% and 70%, respectively. OS, DSS, DFS and LRC for early stage (I-II) and advance stage (III-IV) were 81 and 54%, 86 and 63%, 75 and 45%, and 83 and 57%, respectively. Twenty-two percent recurred locally. Of these failures, 19% were inoperable, 36% were surgically salvaged and 34% refused laryngectomy. Conclusions Our survival rates are comparable with published data. The high refusal rate for salvage total laryngectomy is concerning and needs further study to evaluate the reasons. Cureus 2018-06-01 /pmc/articles/PMC6070066/ /pubmed/30083491 http://dx.doi.org/10.7759/cureus.2730 Text en Copyright © 2018, Adeel et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Otolaryngology
Adeel, Mohammad
Faisal, Muhammad
Rashid, Asma
Usman, Sadaf
Khaleeq, Usman
Abbas, Taskheer
Rehman, Abdul
Malik, Kashif
Hussain, Raza
Jamshed, Arif
An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country
title An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country
title_full An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country
title_fullStr An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country
title_full_unstemmed An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country
title_short An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country
title_sort overview of laryngeal cancer treatment at a tertiary care oncological center in a developing country
topic Otolaryngology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070066/
https://www.ncbi.nlm.nih.gov/pubmed/30083491
http://dx.doi.org/10.7759/cureus.2730
work_keys_str_mv AT adeelmohammad anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT faisalmuhammad anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT rashidasma anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT usmansadaf anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT khaleequsman anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT abbastaskheer anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT rehmanabdul anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT malikkashif anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT hussainraza anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT jamshedarif anoverviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT adeelmohammad overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT faisalmuhammad overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT rashidasma overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT usmansadaf overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT khaleequsman overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT abbastaskheer overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT rehmanabdul overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT malikkashif overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT hussainraza overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry
AT jamshedarif overviewoflaryngealcancertreatmentatatertiarycareoncologicalcenterinadevelopingcountry